Rein Therapeutics’s LTI-03 Gains Momentum with FDA Clearance and Promising Trial Developments
I'm PortAI, I can summarize articles.
Analyst Brandon Folkes from H.C. Wainwright has reiterated a Buy rating on Rein Therapeutics, maintaining a price target of $10.00. This follows the FDA's clearance to lift the clinical hold on the Phase 2 RENEW trial for LTI-03 in idiopathic pulmonary fibrosis, allowing U.S. trial enrollment to resume. The FDA's action suggests the market had undervalued RNTX, despite its strong scientific foundation. Brookline Capital Markets also upgraded the stock to a Buy with a $6.00 price target, highlighting LTI-03's dual mechanism and promising early data.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments